Biotechs and Blockchain are ripping

*together with Option Pit & Brownstone Research

Good day, 360!

Here are some of our top movers today. And don’t forget to join us in Market Masters - b/c if you missed Jeff William’s Weekly Wiretap on IWM, you NEED to tune in for all the action (right now name your own price to get his next pick Monday)! Insane deal!!!

FOCUS LIST🔎

INM - Up over 80% in the pre-market after reporting INM-901 significantly reduces neuroinflammation in Alzheimer's disease ex vivo study  

IBIO - Up over 48% in pre after unveiling obesity program with AstralBio for novel Amylin agonist antibody demonstrating promising in vivo results

NA - Up over 170% in pre after announcing US$500 million convertible notes private placement for BNB treasury strategy

HOTLIST🔥

INM - Up over 80% in the pre-market after reporting INM-901 significantly reduces neuroinflammation in Alzheimer's disease ex vivo study  

InMed Pharmaceuticals Inc. (INM) is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs.

In the pre-market this morning, the company announced new preclinical data demonstrating that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation, further supporting its potential as a therapeutic candidate in Alzheimer's disease.

Highlights include:

Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/Gro

Significantly reduces levels of inflammasome marker, NLRP3, a key contributor to neurodegeneration

Reduces key pro-inflammatory markers, independent of amyloid beta or tau pathology

Share of INM traded up over 80% in the pre-market in reaction to the news.

The first target for bulls is the pre-market high at $5.35. Beyond that, $7, $8, $9.10 and $10 come into play.

Below $5.35, targets to the downside are $5, $4.50, $4, $3.80, $3 and then a gap fill at $2.45. 

IBIO - Up over 48% in pre after unveiling obesity program with AstralBio for novel Amylin agonist antibody demonstrating promising in vivo result

iBio, Inc. (IBIO) is an AI-driven innovator of next-generation antibody therapies. In the pre-market this morning, the company announced preclinical data in which an engineered amylin receptor agonist antibody reduced acute food intake in a mouse model of obesity by 60% (p<0.05), equivalent to the reduction in food intake from a clinically advanced dual amylin and calcitonin receptor agonist (DACRA) peptide (67%). 

The effect on food intake was monitored over various time points in this side-by-side study with the amylin agonist iBio discovered and a DACRA peptide. The study marks the third target to emerge from iBio’s partnership with AstralBio.

Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist

Findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases.

Shares of IBIO traded up over 48% in the pre-market in reaction to the news.

The $1 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $1.10, $1.20, $1.30 and then the pre-market high at $1.45. Beyond that, $1.62, $2 and $2.30 come into play.

Below $1, targets to the downside are $0.90, $.80 and then a gap fill at $0.7124.

NA - Up over 170% in pre after announcing US$500 million convertible notes private placement for BNB treasury strategy

Nano Labs Ltd (NA) is a leading Web 3.0 infrastructure and product solution provider in China.

In the pre-market this morning, the company announced that it has entered into a convertible notes purchase agreement under which the Company has agreed to issue, and several investors have agreed to subscribe for, a convertible promissory notes in the aggregate principal amount of US$500 million.

The Notes will mature in 360 days following the issuance, with no interest accruing on the outstanding principal amount. During 360 days from the date of this Notes, the Notes are convertible, in whole or in part, into the Class A ordinary shares of the Company at the option of the holder thereof. The conversion price is initially US$20 per Ordinary Share, subject to adjustment as set forth in the Notes. 

The Agreement marks an important step in the Company’s strategic growth. As part of this initiative, Nano Labs will conduct a thorough assessment of the security and value of BNB. In the initial phase, the Company plans to acquire US$1 billion worth of BNB via convertible notes and private placements. Over the long term, Nano Labs aims to hold 5% to 10% of BNB’s total circulating supply.

Shares of NA traded  up over 170% in the pre-market in reaction to the news.

The first target for bulls is the pre-market high at $34.73. Beyond that, $47.50, $60 and $70 come into play.

Below $34.73, targets to the downside are $30, $28, $22, $20, $18, $16 and then $12.

MARKET NEWS 📰

Don't miss out on our MOBILE ALERTS!  Some of these alerts have rocketed past the MOON 🌝.  Simply text “RAGE” to 1-(888) 487-1534 📲.

*Disclosure: By texting “RAGE” to 1-(888) 487-1534, you agree to receive promotional messages sent via an autodialer. You also agree to the terms of service and privacy policy. This agreement isn’t a condition of any purchase. Message frequency varies. Message and data rates may apply. Reply STOP to opt out; HELP for more information.